Clinical Trial Update: Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial of azacitidine in patients with relapsed myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia after stem cell tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24